Ambu (AMBU B) Stock Overview
Researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AMBU B from our risk checks.
AMBU B Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ambu A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 63.05 |
| 52 Week High | DKK 125.00 |
| 52 Week Low | DKK 60.85 |
| Beta | 1.37 |
| 1 Month Change | -7.82% |
| 3 Month Change | -25.91% |
| 1 Year Change | -45.88% |
| 3 Year Change | -38.91% |
| 5 Year Change | -80.64% |
| Change since IPO | 3,581.75% |
Recent News & Updates
AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing
Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.AMBU B: Refined Discount Rate And P/E Expectations Will Support Future Upside
Analysts have lowered their price target on Ambu by DKK 12. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions following recent research updates.AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves
Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.AMBU B: Share Repurchase Mandate And Lowered Fair Value Will Support Upside
Analysts have trimmed their price target on Ambu by DKK 12 to reflect updated assumptions on fair value, discount rates and earnings expectations following recent research commentary. Analyst Commentary Bullish Takeaways Bullish analysts view the revised DKK 12 lower price target as still consistent with a supportive fair value range.
AMBU B: Share Buybacks And Margin Discipline Will Support Future Upside
The analyst price target for Ambu has been trimmed by DKK 1 to DKK 138, as analysts factor in slightly more cautious assumptions on growth, margins and discount rates following recent price target adjustments, such as the DKK 12 cut highlighted by JPMorgan. Analyst Commentary Bullish analysts remain focused on how Ambu can justify its current valuation through consistent execution on its growth plans, even as some price targets, including the DKK 12 adjustment flagged by JPMorgan, are recalibrated.Recent updates
AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing
Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.AMBU B: Refined Discount Rate And P/E Expectations Will Support Future Upside
Analysts have lowered their price target on Ambu by DKK 12. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions following recent research updates.AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves
Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.AMBU B: Share Repurchase Mandate And Lowered Fair Value Will Support Upside
Analysts have trimmed their price target on Ambu by DKK 12 to reflect updated assumptions on fair value, discount rates and earnings expectations following recent research commentary. Analyst Commentary Bullish Takeaways Bullish analysts view the revised DKK 12 lower price target as still consistent with a supportive fair value range.AMBU B: Share Buybacks And Margin Discipline Will Support Future Upside
The analyst price target for Ambu has been trimmed by DKK 1 to DKK 138, as analysts factor in slightly more cautious assumptions on growth, margins and discount rates following recent price target adjustments, such as the DKK 12 cut highlighted by JPMorgan. Analyst Commentary Bullish analysts remain focused on how Ambu can justify its current valuation through consistent execution on its growth plans, even as some price targets, including the DKK 12 adjustment flagged by JPMorgan, are recalibrated.
AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook
The analyst price target for Ambu has been reduced from DKK 94.54 to DKK 78.00. This change reflects analysts’ updated assumptions on discount rate, revenue growth, profit margin and future P/E, as highlighted by recent Street research including a DKK 12 target cut.Earnings Miss: Ambu A/S Missed EPS By 8.7% And Analysts Are Revising Their Forecasts
Feb 08
AMBU B: Share Repurchases And Dividend Policy Will Support Future Upside
Analysts have slightly reduced their price target on Ambu, citing modest revisions to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Together, these changes support a more cautious yet still constructive view on the shares.AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside
Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).Ambu A/S' (CPH:AMBU B) Price In Tune With Earnings
Jan 03AMBU B: Dividend And Share Buybacks Will Drive Future Upside Potential
Analysts have trimmed their price target for Ambu slightly, lowering fair value by about 1 dollar per share as modestly slower expected revenue growth and profit margins are only partly offset by a slightly higher future P/E multiple and lower discount rate. What's in the News Ambu has launched a new share repurchase program starting December 10, 2025, allowing buybacks of up to 10% of its share capital under a mandate valid until December 13, 2027 (company announcement) The company announced an annual dividend of DKK 0.41 per share, payable on December 8, 2025, with an ex date of December 4 and record date of December 5, 2025 (company announcement) For fiscal 2025/26, Ambu issued guidance for 10% to 13% organic growth and an EBIT margin of 12% to 14%, or 14% to 16% excluding roughly 2 percentage points of tariff impacts (company guidance) Ambu reaffirmed its 2024/25 financial guidance, maintaining expectations for 12% to 14% organic revenue growth (company guidance) Valuation Changes Fair Value Estimate edged down slightly from DKK 115.59 to DKK 114.79 per share, reflecting a modestly lower fundamental valuation.An Intrinsic Calculation For Ambu A/S (CPH:AMBU B) Suggests It's 34% Undervalued
Dec 12AMBU B: Dividend Initiation And Margin Outlook Will Support Future Upside
Analysts have modestly raised their price target on Ambu by DKK 0.00 to reflect a slightly higher discount rate and updated profitability assumptions, while maintaining largely unchanged views on long term growth and valuation multiples. What's in the News Ambu A/S announced an annual dividend of DKK 0.41 per share, payable on December 8, 2025, with ex-date December 4 and record date December 5, 2025 (Key Developments).We Think Shareholders Are Less Likely To Approve A Pay Rise For Ambu A/S' (CPH:AMBU B) CEO For Now
Nov 27AMBU B: Improved Margins And Dividend Outlook Will Support Bullish Momentum
Analysts have slightly lowered their fair value price target for Ambu from DKK 121.41 to DKK 115.59, citing modest decreases in projected revenue growth and profit margin expectations. What's in the News Ambu A/S announced an annual dividend of DKK 0.4100 per share.AMBU B: Higher Profit Margins Will Drive Hospital Efficiency Improvements
Analysts have revised their fair value estimate for Ambu down from DKK 130.70 to DKK 121.41. They cite a slightly higher discount rate, even though profit margin and revenue growth projections have improved.Ambu (CPH:AMBU B) Has More To Do To Multiply In Value Going Forward
Oct 07Ambu A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 27Is Ambu A/S (CPH:AMBU B) Trading At A 35% Discount?
Aug 11Should You Think About Buying Ambu A/S (CPH:AMBU B) Now?
Jul 12Ambu's (CPH:AMBU B) Earnings Offer More Than Meets The Eye
May 15Is Now The Time To Put Ambu (CPH:AMBU B) On Your Watchlist?
Mar 14Earnings Miss: Ambu A/S Missed EPS By 6.2% And Analysts Are Revising Their Forecasts
Feb 02Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends
Jan 27Revenues Tell The Story For Ambu A/S (CPH:AMBU B) As Its Stock Soars 27%
Jan 12Is It Too Late To Consider Buying Ambu A/S (CPH:AMBU B)?
Dec 31
Innovative aScope 5 Uretero And Sustainable Initiatives Will Accelerate Revenue Growth
Strategic focus on new high-value product launches and sustainability efforts could enhance revenue growth, product adoption, and brand perception while supporting long-term profitability.Here's Why It's Unlikely That Ambu A/S' (CPH:AMBU B) CEO Will See A Pay Rise This Year
Nov 28Ambu's (CPH:AMBU B) Strong Earnings Are Of Good Quality
Nov 13Earnings Miss: Ambu A/S Missed EPS By 54% And Analysts Are Revising Their Forecasts
Nov 07Ambu A/S Just Beat EPS By 15%: Here's What Analysts Think Will Happen Next
Sep 02Here's What's Concerning About Ambu's (CPH:AMBU B) Returns On Capital
Aug 06Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity
Apr 06Returns On Capital Signal Tricky Times Ahead For Ambu (CPH:AMBU B)
Mar 14Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 01A Piece Of The Puzzle Missing From Ambu A/S' (CPH:AMBU B) Share Price
Jan 02Is Ambu A/S (CPH:AMBU B) Trading At A 42% Discount?
Oct 31Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends
Sep 22Shareholder Returns
| AMBU B | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | -4.7% | -6.7% | -0.6% |
| 1Y | -45.9% | -39.2% | -15.7% |
Return vs Industry: AMBU B underperformed the Danish Medical Equipment industry which returned -39.2% over the past year.
Return vs Market: AMBU B underperformed the Danish Market which returned -15.7% over the past year.
Price Volatility
| AMBU B volatility | |
|---|---|
| AMBU B Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DK Market | 9.3% |
| 10% least volatile stocks in DK Market | 3.0% |
Stable Share Price: AMBU B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: AMBU B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 5,200 | Britt Jensen | www.ambu.com |
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators.
Ambu A/S Fundamentals Summary
| AMBU B fundamental statistics | |
|---|---|
| Market cap | DKK 16.71b |
| Earnings (TTM) | DKK 544.00m |
| Revenue (TTM) | DKK 6.09b |
30.7x
P/E Ratio2.7x
P/S RatioIs AMBU B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMBU B income statement (TTM) | |
|---|---|
| Revenue | DKK 6.09b |
| Cost of Revenue | DKK 2.43b |
| Gross Profit | DKK 3.66b |
| Other Expenses | DKK 3.11b |
| Earnings | DKK 544.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 2.05 |
| Gross Margin | 60.07% |
| Net Profit Margin | 8.94% |
| Debt/Equity Ratio | 0.2% |
How did AMBU B perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield20%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 00:08 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ambu A/S is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Michael Healy | Berenberg |
| Susannah Ludwig | Bernstein |